CARsgen Therapeutics Holdings Ltd (2171) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CARsgen Therapeutics Holdings Ltd HK$1.37, price HK$12.45, upside -89.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CARsgen Therapeutics Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$2.59 – HK$54.50 · fair‑value band HK$0.9000 – HK$1.71 · the HK$12.45 price screens above the HK$1.37 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow CARsgen Therapeutics Holdings in your weekly email
Every Wednesday you see whether CARsgen Therapeutics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
Show more
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies. Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.
Stock analysis
CARsgen Therapeutics Holdings Ltd (2171) currently trades at HK$12.45, while our model-based Fair Value estimate is HK$1.37, 89.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: HK$0.9000 (bear) to HK$1.71 (bull), the price of HK$12.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CARsgen Therapeutics Holdings Ltd reported revenue of 126M CNY in FY2025 versus 25.8M CNY in FY2021, a compound +48.5%/yr. Reported net income was −97.9M CNY in FY2025.
Key figures
Market cap HK$8.7B (≈ $1.1B) · P/S ratio 68.9 · EPS (TTM) HK$−0.1400 · Net margin −77.9% · Return on equity −11.2% · Return on assets (EBIT) −27.7% · Operating margin −116% · Revenue (TTM) HK$126M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −89%, 2171 screens richer than that median.
Fair Value models
Bear HK$0.9000Fair Value HK$1.37Bull HK$1.71
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare CARsgen Therapeutics Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Top 25%
Fair Value upside−89.0% · Bottom 25%
Profitability
Return on assets−9.6% · Above median
Net margin (TTM)−77.9% · Bottom 25%
Operating margin (TTM)−116.3% · Bottom 25%
Growth and dividend
Revenue growth125.8% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.41× · Cheaper than median
P/S (TTM)8.78× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CARsgen Therapeutics Holdings Ltd (2171) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.37 versus a price of HK$12.45, about −89% upside (overvalued).
What is the fair value of 2171?
Our model-based fair value for CARsgen Therapeutics Holdings Ltd is HK$1.37 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$12.45.
What is the quality score of 2171?
CARsgen Therapeutics Holdings Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CARsgen Therapeutics Holdings Ltd (2171)?
Our model-based price target is the fair value of HK$1.37 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.9000, optimistic scenario HK$1.71. It is a calculation from audited fundamentals, not an analyst target.
What is the CARsgen Therapeutics Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$1.37, about −89% upside versus a price of HK$12.45 (overvalued). Cautious scenario HK$0.9000, optimistic scenario HK$1.71. The calculation is refreshed regularly with new filings.
What is the revenue of CARsgen Therapeutics Holdings Ltd (2171)?
CARsgen Therapeutics Holdings Ltd reported trailing-twelve-month revenue of about HK$126M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of CARsgen Therapeutics Holdings Ltd (2171)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CARsgen Therapeutics Holdings Ltd it is HK$1.37 per share (as of Sep 27, 2026), against a price of HK$12.45. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CARsgen Therapeutics Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2171 trades above its calculated fair value: price HK$12.45, fair value HK$1.37, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2171?
No. The price is what the market pays today (HK$12.45); the fair value is what the company's own numbers justify (HK$1.37). For CARsgen Therapeutics Holdings Ltd the two are HK$11.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is CARsgen Therapeutics Holdings Ltd worth?
The market values CARsgen Therapeutics Holdings Ltd at about HK$8.7B (market capitalisation, as of Sep 27, 2026). Per share that is HK$12.45; our models calculate a fair value of HK$1.37 per share.
What do the bullish and bearish scenarios say about 2171?
Our models span a range for CARsgen Therapeutics Holdings Ltd: cautious scenario HK$0.9000, base HK$1.37, optimistic HK$1.71 per share (as of Sep 27, 2026, price HK$12.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CARsgen Therapeutics Holdings Ltd (2171)?
Balance-sheet figures for CARsgen Therapeutics Holdings Ltd (as of Sep 27, 2026): return on equity −11.2%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 2171 from its 52-week high?
CARsgen Therapeutics Holdings Ltd trades at HK$12.45, about 53% below its 52-week high of HK$26.58 and 15% above the low of HK$10.87 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.37 is for.
Which stocks are comparable to CARsgen Therapeutics Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CARsgen Therapeutics Holdings Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$12.45, calculated fair value HK$1.37 (−89%), Quality Score 58/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2171 calculated?
We run CARsgen Therapeutics Holdings Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.37, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. CARsgen Therapeutics Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CARsgen Therapeutics Holdings Ltd (2171)?
The closing price on Oct 2, 2026 was HK$12.45. Our model-based fair value is HK$1.37, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CARsgen Therapeutics Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$1.71). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$0.9000 to HK$1.71) leaves room in how you read the outcome.
Key figures of CARsgen Therapeutics Holdings Ltd
How large is the market capitalisation of CARsgen Therapeutics Holdings Ltd (2171)?
The market capitalisation of CARsgen Therapeutics Holdings Ltd is HK$8.7B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CARsgen Therapeutics Holdings Ltd (2171)?
The price-to-sales ratio of CARsgen Therapeutics Holdings Ltd is 68.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CARsgen Therapeutics Holdings Ltd (2171)?
Earnings per share at CARsgen Therapeutics Holdings Ltd are HK$−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CARsgen Therapeutics Holdings Ltd (2171)?
The net margin of CARsgen Therapeutics Holdings Ltd is −77.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CARsgen Therapeutics Holdings Ltd (2171)?
The return on equity (ROE) of CARsgen Therapeutics Holdings Ltd is −11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CARsgen Therapeutics Holdings Ltd (2171)?
On an EBIT basis the return on assets of CARsgen Therapeutics Holdings Ltd is −27.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CARsgen Therapeutics Holdings Ltd (2171)?
The operating margin of CARsgen Therapeutics Holdings Ltd is −116% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CARsgen Therapeutics Holdings Ltd (2171)?
Revenue at CARsgen Therapeutics Holdings Ltd is growing +126% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CARsgen Therapeutics Holdings Ltd (2171) generate?
The free cash flow of CARsgen Therapeutics Holdings Ltd is −HK$243M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CARsgen Therapeutics Holdings Ltd (2171) hold?
CARsgen Therapeutics Holdings Ltd holds more cash than debt, HK$1.1B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CARsgen Therapeutics Holdings Ltd in the live analysis
One click puts CARsgen Therapeutics Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
